gtag('event', 'click', { 'event_category': 'PDF Download' });
was successfully added to your cart.


Health Professionals BlogPortal Hypertension and Ascites

Transjugular intrahepatic portosystemic shunt for pediatric portal hypertension: a meta-analysis

Title: Transjugular intrahepatic portosystemic shunt for pediatric portal hypertension: a meta-analysis

Source: Journal of Clinical Imaging Science 2023, June 26. [E-publication]

Follow this link

Date of publication: June 2023

Publication type: Meta-analysis

Abstract: To evaluate the feasibility of transjugular intrahepatic portosystemic shunt (TIPS) in children with portal hypertensive complications, PubMed and Cochrane Library were queried to identify clinical studies evaluating TIPS in patients <18 years old. Baseline clinical characteristics, laboratory values, and clinical outcomes were extracted. Eleven observational studies totaling 198 subjects were included in the study. The pooled technical success rate and hemodynamic success rate were 94% (95% confidence interval [CI]: 86-99%) and 91% (95% CI: 82-97%), respectively; ongoing variceal bleeding resolved in 99.5% (95% CI: 97-100%); refractory ascites was improved in 96% (95% CI: 69-100%); post-TIPS bleeding rate was 14% (95% CI: 1-33%); 88% of patients were alive or successfully received liver transplant (95% CI: 79-96%); and shunt dysfunction rate was 27% (95% CI: 17-38%). Hepatic encephalopathy occurred in 10.6% (21/198), though 85.7% (18/21) resolved with medical management only. In conclusion, based on moderate levels of evidence, TIPS is a safe and effective intervention that should be considered in pediatric patients with portal hypertensive complications. Future comparative studies are warranted.

Leave a Reply

© 2019 Children's Liver Disease Foundation. All Rights Reserved.